Table 2.

The age of PWS genetic diagnosis and the data at the start of rhGH treatment (the mean value ± standard deviation score, SDS; median (minimal-maximal value) for the age of diagnosis and rhGH start).

PWS Group	All Patients	DEL 15	UPD 15	UPD/ID
Number of patients (%)	N = 147	N = 81 (55.10)	N = 10 (6.80)	N = 30 (20.41)
F/M (%)	69/78 (46.94/53.06)	43/38 (53.09/46.91)	1/9 (10/90)	11/19 (36.67/63.33)
Age of diagnosis [years]	1.67 ± 2.39 0.53 (0.02–12.49)	1.38 ± 2.33 0.41 (0.02–12.49)	3.84 ± 2.86 4.1 (0.13–7.31) (p = 0.003) *	3.13 ± 2.72 2.55 (0.09–8.84) (p = 0.00) *
Age of rhGH start [years]	4.55 ± 3.74 3.03 (0.58–17.43)	4.24 ± 3.81 2.64 (0.58–16.75)	7.30 ± 3.03 8.31 (3.29–10.62) (p = 0.003) *	6.42 ± 3.74 5.62 (0.85–17.43) (p = 0.00)*
rhGH dose (IU/kg/week; mg/kg/day)	0.58 ± 0.16; 0.028 ± 0.008	0.57 ± 0.14; 0.027 ± 0.007	0.61 ± 0.13; 0.029 ± 0.006	0.60 ± 0.16; 0.029 ± 0.008
Height [cm]	96.62 ± 23.31	95.23 ± 24.18	111.78 ± 15.65	107.85 ± 20.34
Height SDS	−2.11 ± 1.50	−1.95 ± 1.53	−2.45 ± 1.07	−2.18 ± 1.57
BMI	18.05 ± 3.99	17.79 ± 3.78	20.55 ± 4.24	19.31 ± 3.40
BMI SDS	0.41 ± 1.55	0.39 ± 1.61	1.16 ± 0.91 (p = 0.14) *	0.86 ± 1.29 (p = 0.15) *
IGF1 [ng/mL]	70.31 ± 55.06	75.80 ± 64.56	84.11 ± 47.63	71.93 ± 38.79
IGF1 SDS	−0.89 ± 0.43	−0.83 ± 0.46	−1.03 ± 0.55	−1.03 ± 0.43 (p = 0.04) **

PWS—Prader–Willi syndrome, DEL 15—deletion of chromosome 15q11-13, UPD 15—uniparental disomy, ID—imprinting defect, F/M—female/male, rhGH—recombinant human growth hormone, BMI—body mass index, IGF1—insulin-like growth factor 1. * group UPD 15 vs. DEL 15, UPD/ID vs. DEL 15, ** group UPD/ID vs. DEL 15.